Finance

Lists
Why is VCYT down 3.34%?
Dive Deeper
VCYT:NASDAQ
Veracyte Inc
$43.16
-3.34%
(-1.49) 1D
$43.16
0.00% (0.00)
After hours
Closed: Oct 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VCYT...
Open
$44.04
High
$44.21
Low
$42.34
Mkt. cap
3.47B
Avg. vol.
1.45M
Volume
1.21M
P/E ratio
30.77
52-wk high
$60.91
52-wk low
$29.46
EPS
$1.40
Beta
1.95
Shares outstanding
80.39M
No. of employees
755
Open
$44.04
High
$44.21
Low
$42.34
Mkt. cap
3.47B
Avg. vol.
1.45M
Volume
1.21M
P/E ratio
30.77
52-wk high
$60.91
52-wk low
$29.46
EPS
$1.40
Beta
1.95
Shares outstanding
80.39M
No. of employees
755
News stories
From web sources and news partners
About Veracyte Inc
CEO-
Employees755
Founded2006
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiteveracyte.com
Analyst ratings
Based on 11 analysts giving stock ratings to VCYT in the past 3 months
Buy
Buy
9
Hold
1
Sell
1
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for VCYT in the last 3 months.
Highest
Current $43.16
$70.00 (+62.19%)
Average
$59.78 (+38.51%)
Lowest
$44.00 (+1.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Westenberg
Piper Sandler
Buy
Maintained
$54.00
+25.1%
09/17/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/15/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/15/2026
Keith Hinton
Freedom Capital Markets
Buy
Reiterated
$66.00
+52.9%
09/15/2026
Michael Matson
Needham
Buy
Reiterated
$69.00
+59.9%
09/15/2026
Lu Li
UBS
Buy
Maintained
$65.00
+50.6%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
$65.00
+50.6%
09/09/2026
Mason Carrico
Stephens
Buy
Maintained
$55.00
+27.4%
08/04/2026
Kallum Titchmarsh
Morgan Stanley
Sell
Reiterated
$44.00
+1.9%
08/04/2026
Kyle Mikson CFA
Canaccord Genuity
Hold
Maintained
$50.00
+15.8%
08/03/2026
Subbu Nambi
Guggenheim
Buy
Reiterated
$65.00
+50.6%
07/31/2026
Tycho Peterson
Jefferies
Buy
Maintained
$70.00
+62.2%
07/08/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
$55.00
+27.4%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
$55.00
+27.4%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
131.87M
140.64M
139.07M
150.32M
Cost of goods sold
34.80M
45.35M
35.20M
35.39M
Cost of revenue
34.80M
45.35M
35.20M
35.39M
Research and development expenses
15.98M
20.85M
27.10M
29.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
54.64M
46.49M
50.84M
59.35M
Operating expense
73.96M
70.67M
81.22M
91.95M
Total operating expenses
108.76M
116.02M
116.42M
127.34M
Operating income
23.11M
24.61M
22.65M
22.98M
Other non operating income
1.00K
-15.00K
3.83M
-
EBT including unusual items
18.89M
40.63M
29.97M
26.52M
EBT excluding unusual items
25.76M
28.05M
29.97M
26.52M
Income tax expense
-248.00K
-515.00K
1.27M
1.03M
Effective tax rate
-1.31%
-1.27%
4.23%
3.89%
Other operating expenses
-
-
-
-
Net income
19.14M
41.15M
28.71M
25.49M
Net profit margin
14.51%
29.26%
20.64%
16.96%
Earnings per share
0.51
0.53
0.52
0.54
Interest and investment income
3.48M
3.54M
3.48M
3.88M
Interest expense
-
-
-
-
Net interest expenses
3.48M
3.54M
3.48M
3.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
28.38M
29.91M
28.08M
27.82M
Gain or loss from assets sale
3.86M
2.84M
366.00K
1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps